

# Chapter 160

## Rheumatoid Arthritis, Rheumatic Fever, and Gout

Warren W. Piette

### REFERENCES

1. Alamanos Y, Drosos AA: Epidemiology of adult rheumatoid arthritis. *Autoimmun Rev* **50**, 2004
2. Scott D, Wolfe F, Huizinga TW: Rheumatoid arthritis. *Lancet* **376**(9746):1094-1108, 2010
3. Liao KP, W KE. Classification and epidemiology of rheumatoid arthritis. In: *Rheumatology*, edited by Hochberg MC et al. Philadelphia, PA, Mosby, 2010
4. Seymour H et al: Anti-TNF agents for rheumatoid arthritis. *Br J Clin Pharmacol* **51**:201, 2001
5. Gorman J et al: Impact of shared epitope genotype and ethnicity on erosive disease: A meta-analysis of 3240 rheumatoid arthritis patients. *Arth Rheum* **50**:400, 2004
6. Agrawal S et al: Compound heterozygosity of HLA-DR4 and DR1 antigens in Asian Indians increases the risk of extra-articular features in rheumatoid arthritis. *Br J Rheumatol* **34**:41, 1995
7. Firestein G: Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. *J Clin Rheum* **11**:S39, 2005
8. Snir O et al: Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. *Arthritis Rheum* **62**(1):44-52, 2010
9. Smith MD, G WJ. The Synovium. In: *Rheumatology*, edited by MC Hochberg et al. Philadelphia, Mosby, 2010
10. Arnett F et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* **31**:315, 1988
11. Jorizzo JL, Daniels JC: Dermatologic conditions reported in patients with rheumatoid arthritis. *J Am Acad Dermatol* **8**:439, 1983
12. Sayah A, English JC III: Rheumatoid arthritis: A review of the cutaneous manifestations. *J Am Acad Dermatol* **53**:191, 2005
13. Brasington Jr RD: Clinical features of rheumatoid arthritis. In: *Rheumatology*, MC Hochberg et al. Philadelphia, PA, Mosby, 2010
14. Ackerman A et al: *Histological Diagnosis of Inflammatory Skin Disease*, 2nd edition. Philadelphia, PA, Lippincott William & Wilkins, 1997
15. Watts R et al: The incidence of rheumatoid vasculitis in the Norwich Health Authority. *Br J Rheumatol* **33**:832, 1994
16. Turesson C, Matteson EL: Extra-articular features of rheumatoid arthritis and systemic involvement. In: *Rheumatology*, edited by MC Hochberg et al. Philadelphia, PA, Mosby, 2010
17. Craig S et al: Cutaneous signs of rheumatic disease: Acral purpuric papules in a patient with rheumatoid arthritis. *Arthritis Rheum* **36**:957, 1994
18. Lakhanpal S et al: Clinical and prognostic significance of vasculitis as an early manifestation of connective tissue disease syndromes. *Ann Intern Med* **101**:743, 1984
19. Sanguenza OP et al. Palisaded neutrophilic granulomatous dermatitis in rheumatoid arthritis. *J Am Acad Dermatol* **47**:251-257, 2002
20. Jorizzo JL, Daniels JC: Dermatologic conditions reported in patients with rheumatoid arthritis. *J Am Acad Dermatol* **8**:439, 1983
21. Williams F, Cohen PR, Arnett F: Accelerated cutaneous nodulosis during methotrexate therapy in a patient with rheumatoid arthritis. *J Am Acad Dermatol* **39**:359-362, 1998
22. Mebazaa A et al: Methotrexate-induced papular eruption following treatment of psoriasis. *Ann Pharmacotherapy* **42**:138-141, 2008
23. Goerttler E et al: Methotrexate-induced papular eruption in patients with rheumatic diseases: A distinctive adverse cutaneous reaction produced by methotrexate in patients with collagen vascular diseases. *J Am Acad Dermatol* **40**:702-707, 1999
24. Maruani A et al: Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. *J Am Acad Dermatol* **57**:S69-71, 2007

25. Yamamoto T: Cutaneous manifestations associated with rheumatoid arthritis. *Rheumatol Int* 29:979-988, 2009
26. Harris E et al: *Kelley's Textbook of Rheumatology*. Philadelphia, Elsevier Saunders, 2005
27. America College of Rheumatology Subcommittee on rheumatoid arthritis guidelines: Guidelines for the management of rheumatoid arthritis: 2002 update. *Arthritis Rheum* 46:328, 2002
28. Anonymous: Drugs for rheumatoid arthritis. *The Medical Letter* 7:37-46, 2009
29. Saag K et al: American College of Rheumatology 2008 recommendations for the use of nonbiologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 59:762, 2008
30. Martin J et al: Adalimumab-induced lupus erythematosus. *Lupus* 17:676-678, 2008
31. Zidi I et al: Golimumab therapy of rheumatoid arthritis: an overview. *Scan J Immunol* 72:75-85, 2010
32. Finckh A et al: The effectiveness of anti-tumor necrosis factor therapy in preventing radiographic joint damage in rheumatoid arthritis. *Arthritis Rheum* 54:54, 2006
33. Fujikawa K et al: Cutaneous vasculitis induced by TNF inhibitors: A report of three cases. *Modern Rheumatol* 20:86-89, 2010
34. Massara A et al: Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: A new "class effect" paradoxical phenomenon. *Sem Arth Rheum* 39:313-319, 2010
35. Calero I, Nieto J, Sanz I: B cell therapies for rheumatoid arthritis: Beyond B cell depletion. *Rheumatic Dis Clin N Am* 36:325-343, 2010
36. Kim MJ et al: Rituximab-induced vasculitis: A case report and review of the medical published work. *J Dermatol* 36:284-287, 2009
37. Ostergaard M et al: Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. *Arthritis Rheum* 62:2227-2238, 2010
38. Maxwell L, Singh JA: Abatacept for rheumatoid arthritis: A Cochrane systematic review. *J Rheumatol* 37:234-245, 2010
39. Geborek P et al: Tumor necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. *Ann Rheum Dis* 64:699, 2005
40. Minden K. Classification and epidemiology of juvenile idiopathic arthritis. In: *Rheumatology*, edited by MC Hochberg et al. Philadelphia, PA, Mosby, 2010
41. Nossent JC. Adult-onset Still's disease. In: *Rheumatology*, edited by MC Hochberg et al. Philadelphia, PA, Mosby, 2010
42. Bagnari V et al: Adult-onset Still's disease. *Rheumatol Int* 30:855-862, 2010
43. Braverman IM: Hypersensitivity syndromes. In: *Skin Signs of Systemic Disease*, 3rd edition. Philadelphia, PA, Saunders, 1998
44. Kieffer C, Bernard C, Dan L: Neutrophilic urticaria dermatosis: A variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 cases and review of the literature. *Medicine* 88:23-31, 2009
45. Gopal M et al: Thrombotic thrombocytopenic purpura and adult onset Still's disease. *Am J Med Sci* 337:373-376, 2009
46. Hot A et al: Reactive hemophagocytic syndrome in adult-onset Still's disease. Clinical features and long-term outcome: A case-control study of 8 patients. *Medicine* 89:37-46, 2010
47. Franchini S et al: Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. *Arth Rheum* 62:2530-2535, 2010
48. Mody GM, M MB: Acute rheumatic fever. In: *Rheumatology*, edited by MC Hochberg et al. Philadelphia, PA, Mosby, 2010
49. Carapentis JR, McDonald M, Wilson NJ: Acute rheumatic fever. *Lancet* 366:155, 2005
50. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. *JAMA* 268:2069, 1992
51. Cann MP et al: Clinical presentation of rheumatic fever in an endemic area. *Arch Dis Child* 95(6):455-457, 2010

52. Wilson JF: In the clinic: Gout. *Ann Intern Med* 152:ITC2-16, 2010
53. Choi HK, Mount DB, Reginato AM: Pathogenesis of gout. *Ann Intern Med* 143:499-516, 2005
54. Terkeltaub RA et al: High versus low dosing of oral colchicine for early acute gout flare. Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arth Rheum* 62:1060-1068, 2010
55. Terkeltaub R: The management of gout and hyperuricemia. In: *Rheumatology*, edited by MC Hochberg et al. Philadelphia, PA, Mosby, 2010
56. Chohan S, Becker MA: Update on emerging urate-lowering therapies. *Curr Opin Rheumatol* 21:143-149, 2009

